Compare Amgen, Inc. (AMGN) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Marqeta Inc — how do they compare? Amgen, Inc. trades at $415.33 (market cap $224.14B), while Marqeta Inc trades at $15.46 (market cap $1.62B). The key difference: Amgen, Inc. is far larger — about 138.4× Marqeta Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| AMGN | MQ | |
|---|---|---|
Market Cap | $224.14B | $1.62B |
Sector | Health | Technology |
52-Week High | $417.20 | $26.00 |
52-Week Low | $271.18 | $15.04 |
Enterprise Value | $267.45B | $935.36M |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Marqeta (MQ) trades at $15.6, down 2.26% on the day, with a bearish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split and shows improving revenue trends, though profitability remains thin. Recent news highlights partnerships with Google and Riskified to expand product offerings and reduce fraud.
The outlook is cautiously optimistic due to revenue growth and strategic expansions, but high valuation ratios and inconsistent earnings pose risks. Analyst consensus is a Buy with a $19 price target, suggesting potential upside if execution improves and margins expand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
